Anti-mitotic drugs (drugs that block cell division or growth of cancer cells) such as vincristine are a mainstay of current treatment regimens for multiple cancers affecting both adults and children, including medulloblastoma (MB).
The clinical efficacy of these treatments is hampered by the emergence of drug-resistant clones following treatment, which can result in patient relapse and the cancer returning. MB is a leading cause of cancer-related death in infants and children with 5-year survival rate of 70%, although for patients with the most aggressive diagnosis, Group 3 (G3), this drops to 50%.
Grant Award – Studentship 2019-2020
Funding Award – £2000
Funding Awarded to – Dr Caroline Topham
Research Location – University of Salford
Lead Researcher – Dr Caroline Topham
0161 295 3864 